Deep Vein Thrombosis Clinical Trial
Official title:
The Effect of Central Venous Catheters on Systemic Coagulation
Hypothesis to be tested: placement of a central venous catheter will induce a systemic hypercoagulable state. To determine this, the investigators will measure thromboelastography (TEG), PT(prothrombin time), PTT (partial thromboplastin time), Prothrombin Fragment 1.2, Factor VIII, and VonWillebrand's Factor. In addition, duplex ultrasound will be performed to correlate the laboratory coagulation values with functional changes (i.e. deep venous thrombosis).
We will enroll all patients who will be getting a Central Venous Catheter (CVC) placed
either in the PICC Insertion Room or in a surgical intensive care unit who are undergoing
emergent central venous catheter placement for a medically indicated reason. All patients
who have not had a previous central line or will be getting their catheter exchanged over
guide wire are eligible.
At Baseline:
We intend to evaluate the patient for a Deep Vein Thrombosis by conducting a duplex
ultrasound of the lower extremities prior to line insertion. We will also collect one sample
of blood at baseline within 3 hours of insertion.
During CVC Insertion:
One sample of blood will be collected during CVC insertion.
Follow Up:
The last blood sample will be collected soon after CVC insertion (approximately 3hrs). Blood
samples will only be drawn when we are available to collect them. Thus, this is defined as a
"sample of convenience". We will also conduct another duplex ultrasound of the extremities
after CVC insertion for evaluation of DVT.
Data will be collected on the duplex ultrasound result, the type of central line and the
exact insertion site. Should a DVT be found, the attending physician will be made aware
according to clinical protocol.
Normally, at the moment of central venous puncture, 5cc of blood is aspirated and wasted to
confirm correct placement of the needle tip before placement of the guidewire. For the
intended study, instead of wasting that blood, we will save 500 microliters of it for
coagulation analysis. Immediately after the catheter is inserted over the guidewire, a chest
x-ray is obtained to verify position of the catheter. At this point, each port of the
central venous catheter is aspirated and wasted before infusion through the central venous
catheter. For the purpose of this study, we will save 500 microliters of that wasted blood
for coagulation analysis. To clarify, the second 500 microliters will be drawn through the
newly placed central venous catheter ports and saved (instead of being drawn and wasted).
Drawing back on each port before infusing is standard practice. This second sample will
contain a small amount of saline, but, based on a few trials in the animal lab, this saline
is unlikely to effect the coagulation analysis.
In summary, we intend to visit the patient 3 times over approximately a 4 hour period for
the purpose of collecting blood that would normally otherwise be wasted (a total of 1500
microliters). This will be done only on patients who are undergoing the procedure for for a
medically indicated reason and medical care will not be changed, affected, or otherwise
altered based on involvement in this study. Our purpose is simply to collect 3 samples of
blood during emergent central venous catheter placement that would otherwise be wasted into
the biohazard container.
We will use this blood to assay prothrombin time, partial thromboplastin time,
thromboelastography, Prothrombin Fragment 1.2, Factor VIII, and VonWillebrand's Factor.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05003843 -
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
|
N/A | |
Recruiting |
NCT03937947 -
Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
|
||
Withdrawn |
NCT04136561 -
Novel Strategy to Encourage Early Removal of Central Venous Catheters
|
N/A | |
Completed |
NCT03420625 -
Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Completed |
NCT02555111 -
Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.
|
Phase 3 | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Terminated |
NCT02469376 -
Evaluation of a New Imagingtechnologie for Thrombosis
|
Phase 1 | |
Completed |
NCT02037607 -
Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00244725 -
Odiparcil For The Prevention Of Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT00264277 -
D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism
|
Phase 4 | |
Completed |
NCT00365950 -
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
|
Phase 4 | |
Completed |
NCT00182403 -
Fixed Dose Heparin Study
|
Phase 3 | |
Completed |
NCT03682419 -
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
|
N/A | |
Not yet recruiting |
NCT04981327 -
The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis
|
Phase 3 | |
Recruiting |
NCT03240120 -
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
|
Phase 3 |